Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Solid Tumor × magrolimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 3 Squamous Cell Carcinoma of Head and Neck 2 Colorectal Neoplasms 2 Triple Negative Breast Neoplasms 1 Solid Tumor 1 Sezary Syndrome 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neuroblastoma 1 Myeloid Malignancies 1 Mycosis Fungoides 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1

Interventions

pertuzumab 2 durvalumab 2 Paclitaxel 2 Nivolumab 2 Docetaxel 2 Capecitabine 2 ulocuplumab 1 tremelimumab 1 tazarotene 1 talazoparib 1 romiplostim 1 pexidartinib 1 pembrolizumab 1 pamiparib 1 magrolimab 1 entrectinib 1 cobimetinib 1 atezolizumab 1 Sunitinib 1 Rifampin 1 Radiosurgery 1 Midazolam 1 LY3022855 1 LY2510924 1 Itraconazole 1 Irinotecan 1 Ipilimumab 1 Dextromethorphan 1 Carboplatin 1 CH5183284 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04827576 2025-05-08

ELEVATELung&UC

Gilead Sciences

Phase 2 Terminated

106 enrolled 22 charts

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡